News | July 07, 2022
Lonza to build large-scale fill & finish facility in Switzerland
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Acceptance based on results from the phase 3 KEYNOTE-091 trial
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
Subscribe To Our Newsletter & Stay Updated
